Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine.
SARS-CoV-2
mRNA vaccines
neutralizing antibodies
spike antibodies
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
25 Oct 2021
25 Oct 2021
Historique:
received:
28
09
2021
revised:
20
10
2021
accepted:
22
10
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Subjects with previous COVID-19 have augmented post-vaccination responses. However, the antibody response in COVID-naïve subjects from Southeast Asia is not well known. 77 COVID-naïve vaccinees were tested with a full antibody panel [spike antibodies (total (T-Ab), IgG, IgM) and neutralizing antibodies (N-Ab)] pre-vaccination, 10 days after dose 1, and 20/40/60/90/120/150/180 days after dose 2. 10 days after dose 1, 67.6% (48/71)/69.0% (49/71) were T-Ab/IgG positive; only 15.5% (11/71)/14.1% (10/71) were N-Ab/IgM positive. While all (100%) subjects had brisk T-Ab, IgG and N-Ab antibody responses 20 days after complete vaccination, only 79.1% (53/67) were IgM positive. At 180 days ( The antibody responses of T-Ab, IgG and N-Ab remain high and durable even at 180 days. N-Ab titers are expected to remain reactive up to 241 days post-vaccination.
Sections du résumé
BACKGROUND
BACKGROUND
Subjects with previous COVID-19 have augmented post-vaccination responses. However, the antibody response in COVID-naïve subjects from Southeast Asia is not well known.
METHODS
METHODS
77 COVID-naïve vaccinees were tested with a full antibody panel [spike antibodies (total (T-Ab), IgG, IgM) and neutralizing antibodies (N-Ab)] pre-vaccination, 10 days after dose 1, and 20/40/60/90/120/150/180 days after dose 2.
RESULTS
RESULTS
10 days after dose 1, 67.6% (48/71)/69.0% (49/71) were T-Ab/IgG positive; only 15.5% (11/71)/14.1% (10/71) were N-Ab/IgM positive. While all (100%) subjects had brisk T-Ab, IgG and N-Ab antibody responses 20 days after complete vaccination, only 79.1% (53/67) were IgM positive. At 180 days (
CONCLUSIONS
CONCLUSIONS
The antibody responses of T-Ab, IgG and N-Ab remain high and durable even at 180 days. N-Ab titers are expected to remain reactive up to 241 days post-vaccination.
Identifiants
pubmed: 34835172
pii: vaccines9111241
doi: 10.3390/vaccines9111241
pmc: PMC8622758
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Vaccines (Basel). 2021 Sep 28;9(10):
pubmed: 34696200
Clin Infect Dis. 2021 Mar 08;:
pubmed: 33693643
JAMA. 2021 Oct 19;326(15):1533-1535
pubmed: 34459863
Clin Chem. 2021 Jan 30;67(2):404-414
pubmed: 33084854
Nat Microbiol. 2021 Sep;6(9):1140-1149
pubmed: 34290390
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
N Engl J Med. 2021 Oct 6;:
pubmed: 34614326
Clin Infect Dis. 2021 Apr 27;:
pubmed: 33906236
J Appl Lab Med. 2021 Mar 1;6(2):491-495
pubmed: 33098417
Clin Chim Acta. 2020 Nov;510:760-766
pubmed: 32910979
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Cells. 2021 Jul 31;10(8):
pubmed: 34440721
Viruses. 2021 Jul 14;13(7):
pubmed: 34372570
Clin Chem Lab Med. 2020 Dec 18;59(5):e179-e183
pubmed: 33554588
Microorganisms. 2021 Mar 08;9(3):
pubmed: 33800489
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
EClinicalMedicine. 2021 Aug;38:101018
pubmed: 34278286
J Appl Lab Med. 2020 Nov 1;5(6):1313-1323
pubmed: 32717060
Nat Commun. 2021 Jun 28;12(1):3991
pubmed: 34183681
Emerg Microbes Infect. 2021 Dec;10(1):1495-1498
pubmed: 34232116
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Pract Lab Med. 2021 May;25:e00230
pubmed: 33937471
N Engl J Med. 2021 Oct 7;385(15):1355-1371
pubmed: 34496194